DANUBE AG |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 105.6 CHF | +1.10% |
|
-0.28% | +14.84% |
| 31/05 | Dsm-firmenich to Build Centralized Financing Structure Under Cross Guarantee Deal | MT |
| 28/05 | Elanco Says FDA Confirms Bovaer Meets Safety, Efficacy Requirements | MT |
| Sales 2024 * | 1.26TCr 1.37TCr 1.23TCr 1,14200Cr | Sales 2025 * | 1.33TCr 1.44TCr 1.3TCr 1,20100Cr | Capitalization | 2.8TCr 3.04TCr 2.74TCr 2,53700Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 45Cr 49Cr 44Cr 4.1TCr | Net income 2025 * | 81Cr 88Cr 79Cr 7.33TCr | EV / Sales 2024 * | 2.46 x |
| Net Debt 2024 * | 295.13Cr 320.06Cr 288.74Cr 27TCr | Net Debt 2025 * | 269.06Cr 291.8Cr 263.24Cr 24TCr | EV / Sales 2025 * | 2.32 x |
| P/E ratio 2024 * |
60.7
x | P/E ratio 2025 * |
34.8
x | Employees | 28,685 |
| Yield 2024 * |
2.38% | Yield 2025 * |
2.34% | Free-Float | 25.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Danube AG
More press releases
| 1 day | +1.10% | ||
| 1 week | -0.28% | ||
| 1 month | -0.05% | ||
| 3 months | +5.57% | ||
| 6 months | +22.82% | ||
| Current year | +14.84% |
1 week
103.55
107.50
1 month
102.30111.10
Current year
85.86111.10
1 year
75.45111.10
3 years
75.45122.06
5 years
75.45122.06
10 years
75.45122.06
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 01/90/01 | |
Ralf Schmeitz
DFI | Director of Finance/CFO | - | 01/23/01 |
Sarah Reisinger
CTO | Chief Tech/Sci/R&D Officer | 45 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 01/23/01 | |
Thomas Leysen
CHM | Chairman | 63 | 01/23/01 |
| Director/Board Member | 62 | 01/23/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.82% | 12 M€ | +15.09% | - | |
| 0.51% | 10 M€ | +6.14% | - | |
| 0.37% | 88 M€ | +10.37% | - | |
| 0.22% | 4 M€ | -.--% | - | |
| 0.20% | 6 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 105.6 | +1.10% | 840,472 |
| 30/24/30 | 104.5 | -0.76% | 393,338 |
| 29/24/29 | 105.3 | -1.17% | 390,824 |
| 28/24/28 | 106.6 | -0.14% | 296,376 |
| 27/24/27 | 106.7 | +0.71% | 105,449 |
End-of-day quote Euronext Amsterdam, May 31, 2024
More quotes
DSM-Firmenich AG is a leading innovator in nutrition, health, and beauty. It reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world's growing population to thrive. With a comprehensive range of natural and renewable ingredients and renowned science and technology capabilities, the company uniquely works to create what is essential for life, desirable for consumers, and more sustainable for the planet.
Sector
Consumer Goods Conglomerates
Calendar
03/06/2024
- Capital Markets Day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
105.6
EUR
Average target price
121.9
EUR
Spread / Average Target
+15.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.84% | 3.04TCr | |
| +15.62% | 90TCr | |
| +1.88% | 24TCr | |
| +29.39% | 18TCr | |
| +58.75% | 9.52TCr | |
| -7.33% | 7.24TCr | |
| -8.40% | 5.54TCr | |
| +36.57% | 3.63TCr | |
| -42.23% | 2.96TCr | |
| +66.00% | 2.92TCr |
- Stock Market
- Equities
- DSFIR Stock
